# Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

> **NCT02499120** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 125 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck (SCCHN)

## Interventions

- **DRUG:** palbociclib
- **DRUG:** Cetuximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02499120
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-10
- **Primary completion:** 2018-07-19
- **Final completion:** 2022-09-07
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499120, "Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02499120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*